Atomoxetine (Strattera) for the treatment of Attention Deficit Hyperactivity Disorder
The Medicinal Products Reimbursement Committee (CFH) has carried out a re-assessment of the medicine atomoxetine (Strattera). Atomoxetine is intended, as part of a broad treatment programme, for the attention deficit hyperactivity disorder (ADHD) in children aged 6 years and older and adolescents.
The conclusion of earlier assessments was that evidence of clinically relevant differences in properties between atomoxetine and methylphenidate was lacking or insufficient. This is one of the criteria that led to atomoxetine being clustered with methylphenidate on List 1A.